Glenmark Pharma has received final approval for Colesevelam Hydrochloride, from USFDA.

Colesevelam Hydrochloride is a generic version of Welchol 1 of Daiichi Sankyo Inc and the company has received approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet. Furthermore, the company has completed the formalities for the acquisition of the equity stake and has acquired the 100% equity share holding of Zorg.

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week